Takuji Iwase

Futoshi Akiyama9
Rie Horii7
9Futoshi Akiyama
7Rie Horii
Learn More
BACKGROUND The impact of sentinel lymph node biopsy on breast cancer mimicking ductal carcinoma in situ (DCIS) is a matter of debate. METHODS We studied the rate of occurrence of sentinel lymph node metastasis in 255 breast cancer patients with pure DCIS showing no invasive components on routine pathological examination. We compared this to the rate of(More)
Introduction The incidence of breast cancer has increased greatly in Japan over the past 2 decades [1], and it has been estimated that breast cancer would become the most common malignant disease in Japanese females by the year 2000 [2]. One of the main risk factors for breast cancer in menopausal women is obesity [3,4]. The increased amount of adipose(More)
The architectural distortion is a very important finding in interpreting breast cancers as well as microcalcification and mass on mammograms. However, it is more difficult for physicians to detect architectural distortion than microcalcification and mass. The purpose of this study is to develop two detection approaches for architectural distortions existing(More)
  • Ippei Fukada, Kazuhiro Araki, Kokoro Kobayashi, Tomoko Shibayama, Masaru Hatano, Shunji Takahashi +3 others
  • 2016
INTRODUCTION Pulmonary tumor thrombotic microangiopathy (PTTM) is rare, cancer-related pulmonary complication leading to hypoxia, pulmonary hypertension, and heart failure. The standard treatment for PTTM is not established. However, imatinib, a tyrosine kinase inhibitor of the PDGF receptor, may cause regression of pulmonary hypertension and pulmonary(More)
Eribulin is a non-taxane, microtubule dynamics inhibitor that increases survival of patients with metastatic breast cancer. Although eribulin is well tolerated in patients with heavily pretreated disease, eribulin-induced liver dysfunction (EILD) can occur, resulting in treatment modification and subsequent poor disease control. We aimed to clarify the(More)
  • Ippei Fukada, Kazuhiro Araki, Kokoro Kobayashi, Tomoko Shibayama, Shunji Takahashi, Rie Horii +7 others
  • 2016
BACKGROUND Pathological complete response (pCR) with neoadjuvant chemotherapy (NAC) has been regarded as a surrogate endpoint for disease-free survival (DFS) and overall survival (OS) of patients with breast cancer. No consensus regarding the definition of pCR has been established; there are several definitions according to a variety of classifications.(More)